Atricure Stock Performance
| ATRC Stock | USD 35.68 0.35 0.97% |
On a scale of 0 to 100, AtriCure holds a performance score of 13. The firm shows a Beta (market volatility) of 1.31, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, AtriCure will likely underperform. Please check AtriCure's treynor ratio, kurtosis, relative strength index, as well as the relationship between the downside variance and day median price , to make a quick decision on whether AtriCure's price patterns will revert.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in AtriCure are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather conflicting basic indicators, AtriCure exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.0139 | Five Day Return 1.68 | Year To Date Return 2.02 | Ten Year Return 102.79 | All Time Return 155.93 |
1 | Radiofrequency Ablation Device Market Global Forecast Report and Company Analysis 2024-2032 Featuring Boston Scientific, Abbott, AtriCure, Medtronic, Stryker, S... | 09/13/2024 |
2 | AtriCure launches new CryoSphere Max cryoablation probe | 10/15/2024 |
3 | AtriCure Inc Shares Up 21.47 percent on Oct 30 | 10/30/2024 |
4 | Is It Time To Consider Buying AtriCure, Inc. | 10/31/2024 |
5 | US42.67 - Thats What Analysts Think AtriCure, Inc. Is Worth After These Results | 11/01/2024 |
6 | AtriCure Inc Shares Up 3.58 percent on Nov 5 | 11/05/2024 |
7 | Perkins Capital Management Inc. Sells 500 Shares of AtriCure, Inc. | 11/07/2024 |
8 | ATRCs VentureOne Launches QuantumGate to Secure Data for the Quantum Era at CyberQ | 11/12/2024 |
9 | VentureOne de ATRC lanza QuantumGate para resguardar datos para la era cuntica en CyberQ | 11/14/2024 |
10 | Disposition of 4417 shares by Dahlquist Karl S. of AtriCure at 44.83 subject to Rule 16b-3 | 11/15/2024 |
11 | AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference | 11/20/2024 |
| Begin Period Cash Flow | 58.1 M |
AtriCure |
AtriCure Relative Risk vs. Return Landscape
If you would invest 2,615 in AtriCure on August 24, 2024 and sell it today you would earn a total of 953.00 from holding AtriCure or generate 36.44% return on investment over 90 days. AtriCure is currently generating 0.5386% in daily expected returns and assumes 3.091% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than AtriCure, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AtriCure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AtriCure's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AtriCure, and traders can use it to determine the average amount a AtriCure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1743
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ATRC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.09 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.54 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average AtriCure is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AtriCure by adding it to a well-diversified portfolio.
AtriCure Fundamentals Growth
AtriCure Stock prices reflect investors' perceptions of the future prospects and financial health of AtriCure, and AtriCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AtriCure Stock performance.
| Return On Equity | -0.0839 | ||||
| Return On Asset | -0.0351 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 1.72 B | ||||
| Shares Outstanding | 48.75 M | ||||
| Price To Earning | 33.47 X | ||||
| Price To Book | 3.81 X | ||||
| Price To Sales | 3.96 X | ||||
| Revenue | 399.25 M | ||||
| Gross Profit | 245.94 M | ||||
| EBITDA | (8.11 M) | ||||
| Net Income | (30.44 M) | ||||
| Cash And Equivalents | 118.45 M | ||||
| Cash Per Share | 2.55 X | ||||
| Total Debt | 74.49 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | 9.54 X | ||||
| Cash Flow From Operations | 4.48 M | ||||
| Earnings Per Share | (0.82) X | ||||
| Market Capitalization | 1.77 B | ||||
| Total Asset | 613.93 M | ||||
| Retained Earnings | (357.06 M) | ||||
| Working Capital | 191.68 M | ||||
| Current Asset | 74.75 M | ||||
| Current Liabilities | 31.59 M | ||||
About AtriCure Performance
By analyzing AtriCure's fundamental ratios, stakeholders can gain valuable insights into AtriCure's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AtriCure has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AtriCure has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 250.64 | 130.50 | |
| Return On Tangible Assets | (0.10) | (0.10) | |
| Return On Capital Employed | (0.05) | (0.05) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.07) | (0.07) |
Things to note about AtriCure performance evaluation
Checking the ongoing alerts about AtriCure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AtriCure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AtriCure appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 399.25 M. Net Loss for the year was (30.44 M) with profit before overhead, payroll, taxes, and interest of 245.94 M. | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference |
- Analyzing AtriCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AtriCure's stock is overvalued or undervalued compared to its peers.
- Examining AtriCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AtriCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AtriCure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AtriCure's stock. These opinions can provide insight into AtriCure's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AtriCure Stock analysis
When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |